{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:26:22Z","timestamp":1793060782148,"version":"4.5.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,30]]},"abstract":"<jats:title>Vignette<\/jats:title>\n                  <jats:p>Treatment decisions are being made for a 74-yr-old woman with multiple and recent vertebral fractures. Romosozumab therapy is considered because of its superior efficacy compared to other osteoporosis therapies. However, because of her age, well-controlled hypertension, and mild hyperlipidemia, she is, according to a risk calculator, at high risk for cardiovascular (CV) disease. Romosozumab is contraindicated for patients at very high risk of CV disease, and clinicians are advised to consider the skeletal benefits vs the potential CV risks in patients with CV risk factors. The background information leading to that contraindication and recent real-world evidence about the relationship between romosozumab and CV risk is reviewed to aid in the discussion with the patient and her primary care provider.<\/jats:p>","DOI":"10.1093\/jbmr\/zjaf164","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T13:59:45Z","timestamp":1762264785000},"page":"382-386","source":"Crossref","is-referenced-by-count":7,"title":["Considerations regarding the use of romosozumab in a patient at high risk for cardiovascular disease"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7827-0778","authenticated-orcid":false,"given":"Michael R","family":"McClung","sequence":"first","affiliation":[{"name":"Oregon Osteoporosis Center , Portland, OR 97239,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"issue":"15","key":"2026033010082552500_ref1","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"2026033010082552500_ref2","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s00198-020-05379-z","article-title":"Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab","volume":"31","author":"Cummings","year":"2020","journal-title":"Osteoporos Int"},{"issue":"3","key":"2026033010082552500_ref3","doi-asserted-by":"publisher","first-page":"e80089","DOI":"10.7759\/cureus.80089","article-title":"Beyond the bone health: a narrative review unveiling the role of bisphosphonates in reducing the risk of myocardial infarction","volume":"17","author":"Tabasum","year":"2025","journal-title":"Cureus."},{"issue":"1","key":"2026033010082552500_ref4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/jbmr.3860","article-title":"Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women","volume":"35","author":"Reid","year":"2020","journal-title":"J Bone Miner Res"},{"key":"2026033010082552500_ref5","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.atherosclerosis.2016.06.039","article-title":"Bisphosphonates for cardiovascular risk reduction: a systematic review and meta-analysis","volume":"252","author":"Kranenburg","year":"2016","journal-title":"Atherosclerosis."},{"key":"2026033010082552500_ref6","doi-asserted-by":"publisher","first-page":"104697","DOI":"10.1016\/j.yrtph.2020.104697","article-title":"Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture","volume":"115","author":"Turk","year":"2020","journal-title":"Regul Toxicol Pharmacol"},{"key":"2026033010082552500_ref7","author":"Pharmaceuticals and Medical Devices Agency","year":"2025"},{"issue":"10","key":"2026033010082552500_ref8","doi-asserted-by":"publisher","first-page":"e1978","DOI":"10.1210\/clinem\/dgae173","article-title":"Cardiovascular safety of romosozumab vs. PTH analogs for osteoporosis treatment: a propensity score matched cohort study","volume":"109","author":"Stokar","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026033010082552500_ref9","doi-asserted-by":"publisher","first-page":"zjaf010","DOI":"10.1093\/jbmr\/zjaf010","article-title":"Comparative cardiovascular safety of romosozumab versus bisphosphonates in Japanese patients with osteoporosis: a new-user, active comparator design with instrumental variable analyses","volume":"17","author":"Tominaga","year":"2025","journal-title":"J Bone Miner Res"},{"key":"2026033010082552500_ref10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40264-024-01475-9","article-title":"Cardiovascular safety of romosozumab compared to commonly used anti-osteoporosis medications in postmenopausal osteoporosis: a systematic review and network meta-analysis of randomized controlled trials","volume":"48","author":"Cheng","year":"2025","journal-title":"Drug Saf"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjaf164\/65173605\/zjaf164.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/41\/4\/382\/65173605\/zjaf164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/41\/4\/382\/65173605\/zjaf164.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T14:08:32Z","timestamp":1774879712000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/41\/4\/382\/8314007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":10,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,11,4]]},"published-print":{"date-parts":[[2026,3,30]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjaf164","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2025,11,4]]}}}